Cancer Treatment Centers of America (CTCA), a national network of five hospitals that specialize in the treatment of patients fighting complex or advanced-stage cancer, has appointed Maurie Markman, M.D., president of the company's Medicine & Science unit, where he will be responsible for advancing the organization's overall commitment to clinical excellence, innovation, safety and patient satisfaction. Markman was senior vice president of Clinical Affairs and national director of Medical Oncology at CTCA.
Gerard van Grinsven, CTCA president and CEO, said, “His expertise in the field of medical oncology and clinical research, combined with his pioneering work in the emerging field of advanced genomic testing, will ensure we continue to deliver the very best clinical care to our patients."
Markman will assume oversight of the CTCA national clinical team, with a focus on the application of all clinical and translational research to patient care. With experience in research on gynecologic malignancies, new drug development and novel management strategies,
Markman worked in a variety of clinical leadership and academic positions cancer institutions prior to joining CTCA in 2010, including the Cleveland Clinic, the University of Texas—MD Anderson Cancer Center, Ohio State University, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College and the University of California San Diego School of Medicine.